Nephrogenic systemic fibrosis in Japan: Advisability of keeping the administered dose as low as possible

Radiology

Volumn 247, Issue 3, 2008, Pages 915-

  Tsushima, Yoshito ^a   Takahashi Taketomi, Ayako ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; MAGNESCOPE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DRUG DERIVATIVE; GADOBENIC ACID; GADODIAMIDE; GADOVERSETAMIDE; HETEROCYCLIC COMPOUND; MEGLUMINE; ORGANOMETALLIC COMPOUND;

CHRONIC KIDNEY DISEASE; CONTRAST ENHANCEMENT; HEMODIALYSIS; HUMAN; INCIDENCE; JAPAN; LETTER; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; CHEMICALLY INDUCED DISORDER; FIBROSIS; KIDNEY FAILURE; NOTE; RISK; RISK FACTOR;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; RISK; RISK FACTORS;

EID: 45149087446     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2473072101     Document Type: Letter

References (6)

1. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008;246:11-14.
2. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-267.
3. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-175.
4. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
5. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-592.
6. ESUR guideline: gadolinium based contrast media and nephrogenic systemic fibrosis. European Society of Urogenital Radiology (ESUR) Web site.http://www.esur.org/Nephrogenic-Fibrosis.39.0.html. Accessed November 12 2007.